Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 34HER2-positive Breast Cancer 5Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Meningeal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms by Site 1Metastatic Breast Cancer With a Isolated Brain Progression 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1Central Nervous System Diseases 1Breast Diseases 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage IA Breast Cancer AJCC v8 1

Interventions

Fulvestrant 4ribociclib 3palbociclib 3abemaciclib 3Anastrozole 3selpercatinib 2exemestane 2Trastuzumab 2Letrozole 2Gonadotropin-Releasing Hormone 2Docetaxel 2AZD9833 2tucatinib 1ipatasertib 1glutathione pegylated liposomal doxorubicin 1entinostat 1elacestrant 1atezolizumab 1alectinib 1Zoledronic Acid 1Watchful Waiting 1Trabectedin 1Tamoxifen 1Sodium Chloride 1STX-478 1RAD1901 1Paclitaxel 1Metformin 1Imlunestrant 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × tucatinib × Breast × Clear all
NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡